ÇENE KEMİKLERİNİN OSTEONEKROZUNA NEDEN OLAN İLAÇLAR ve AJANLAR

İlaç kullanımına bağlı çene kemiklerinin osteonekrozu, maksilla ve mandibulada kan desteğinin bozulması sonucunda kemik nekrozu ve ilerleyici kemik yıkımı ile gelişir. Etiyolojisinde kemik metabolizması hastalıklarının birçoğu ve malignitelerin tedavisinde kullanılan bifosfanatlar önemli rol oynar. Bifosfonatların dışında çeşitli ilaçların ve ajanların da çene kemiklerinde osteonekroza sebebiyet verdiği belirlenmiştir. 2009 yılında bifosfonat kullanımı ile ilişkilendirilen çenelerin osteonekrozu, 2014 yılında çenelerin ilaç kullanımına bağlı osteonekrozu olarak tanımlanmıştır. Bu derlemenin amacı çenelerin ilaç kullanımına bağlı gelişen osteonekrozunun etiyolojisinde rol oynayan ilaçlar ve ajanlarla ilgili bilgi vermektir.

Anahtar Kelimeler:

Bifosfonat, , çene, , etiyoloji, , ilaç ile ilişkili osteonekroz

PDF

___

Biçer AZY. Bifosfonatlar ve çenelerde görülen osteonekroz. Acta Odontologica Turcica 2013;30(1):35-8.
Ertaş ET, Atıcı MY. Bifosfonatlar ve çene kemiğinde görülen osteonekroz. Selcuk Dental Journal, 2015; 2: 91-100.
Yazıcı T, Şentürk MF, Koçer G. İlaca Bağlı Olarak Görülen Çene Kemiklerinde Görülen Osteonekroz (Mronj): Derleme. Sdü Sağlık Bilimleri Enstitüsü Dergisi 2017(1).
Duygu Çapar G , Cabbar F , Yalçın M , Özcakır Tomruk C . İlaçlara Bağlı Çene Kemiği Osteonekrozu: Derleme. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2016; 25(13): 0-0.
Doğan Onur Ö, Atalay B. Anti-rezorptif İlaç Tedavisinin Ağızda Yarattığı Sorunlara Güncel Yaklaşım. Ünür M, editör. Ağız Kanserlerinin Tanı, Tedavi ve Prognozu. 1. Baskı. Ankara: Türkiye Klinikleri; 2019. p.34-9.
Tozoğlu S, Şimşek Kaya G. Çenelerde Görülen Bifosfonatlarla İlişkili Osteonekrozlar. Turkiye Klinikleri J Oral Maxillofac Surg-Special Topics. 2016;2(2):131-42.
Ersan N. Çenelerin İlaç Kullanımına Bağlı Nekrozu (MRONJ): Hangi Noktadayız?. İlgüy D, editör. Ağız Hastalıkları. Ankara: Türkiye 2018. p.86-97.
Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, Yoshikawa K, Kon M. Osteonecrosis of the jaw associated with everolimus: A case report. Mol Clin Oncol. 2017 Feb;6(2):255-257.
Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, Badalamenti G, Russo A, Gebbia N. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol. 2007 Jun;18 Suppl 6:vi168-72. Review.
Onur ÖD, Kurtuluş B, Çevik P. Bifosfonat Kullanan Hastalarda Oral Cerrahi Uygulamalarda Karşilaşilabilecek Sorunlar Ve Tedavisi Oral Complications And Treatments In Patients Receiving Bisphosphonates. Journal of Istanbul University Faculty of Dentistry 2009;43: 113-22.
SS Soydan, F Veziroğlu Şenel, K Araz. Bisfosfonata bağlı olarak çene kemiklerinde gelişen osteonekrozun patogenezi ve tedavisi. Hacettepe Üni Diş Hek Fak Derg 2009;33(3):61-8.
Süer B , Coşkunses F , Sinanoğlu A , Atıl F , Koçyiğit İ , Kan B , Tekin U . Bifosfanat kullanımına bağlı çenelerde gelişen osteonekrozlar: Çok merkezli retrospektif çalışma. Selcuk Dental Journal. 2014; 1(2): 83-77.
Magremanne M, Picheca S, Reychler H. Etiologic diagnosis of jaw osteonecrosis, other than bisphosphonate and radiotherapy related osteonecrosis. Rev Stomatol Chir Maxillofac Chir Orale. 2014 Feb;115(1):45-50.
Tenore G, Palaia G, Gaimari G et al. Medication-Related Osteonecrosis of the Jaws (MRONJ): Etiological Update. Senses Sci 2014; 1 (4):147-152.
Eid A, Atlas J. The role of bisphosphonates in medical oncology and their association with jaw bone necrosis. Oral Maxillofac Surg Clin North Am. 2014 May;26(2):231-7.
Cizmeci Senel F, Saracoglu Tekin U, Durmus A, Bagis B. Severe Osteomyelitis of the Mandible Associated With the Use of Non–NitrogenContaining Bisphosphonate (Disodium Clodronate): Report of a Case. J Oral Maxillofac Surg 65:562-565, 2007.
Göller Bulut D , Özcan G , Avcı F . Assessment Of Osseous Densıty Changes In Patıents Wıth Medıcatıon-Related Osteonecrosıs Of The Jaws Usıng Cone-Beam Ct: A Case Control Study. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi. 2018; 20(2): 146-138.
Pozzi S, Anesi A, Generali L, Bari A, Consolo U, Chiarini L. Bisphosphonate-related osteonecrosis of the jaw (BRONJ). Complications in Endodontic Surgery: Springer; 2014. p. 153-65.
Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jul;106(1):5-13.
Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007 Sep;41(3):318-20. Epub 2007 May 10. Review.
Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008 May;66(5):839-47.
Green JR. Antitumor effects of bisphosphonates. Cancer. 2003 Feb 1;97(3 Suppl):840-7. Review.
Kurban S, Mehmetoglu I: Osteoprotegerin, RANK and RANK ligand. Turkish Journal Of Biochemistry-Türk Biyokimya Dergisi 2007, 32(4):178-184.
Balta O, Kurnaz R, Aytekin K, Aşçı M, Gedikbaş M, Bostan B. Denosumab Therapy in Giant Cell Bone Tumor: Review of Literature. Acta Oncologica Turcica 2017; 50(3): 250-258.
Diz P, López-Cedrún JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc. 2012 Sep;143(9):981-4.
Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. J Dent Res. 2015 Apr;94(4):534-9.
Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev. 2015 May;41(5):455-64.
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29(9): 1221-7
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768): 813–22.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 2014;72(10):1938-56.
Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer therapies and jaw necrosis. Br Dent J 2015;219(5):203-7.
Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002 Oct;2(10):727-39. Review.
Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2006 Jul;4(7):808-21. Epub 2006 Jun 22. Review.
Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110(4): 463-9.
Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2012; 113(3): e1-3.
King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Apr;127(4):289-299
Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg. 2017 Apr;43(2):120-124.
Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori. 2016 Nov 11;102(Suppl. 2).
Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F. Regorafenib Also Can Cause Osteonecrosis of the Jaw. J Natl Cancer Inst. 2016 Feb 7;108(4).
Patel V, Sproat C, Kwok J, Tanna N. Axitinib-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Nov;124(5):e257-e260.
Jung TY. Cases MS. Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient. Oral and Maxillofacial Surgery Cases 2017;3(2):27-33.
Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J. 2015 Dec;60(4):528-31.
Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Feb;125(2):157-163.
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005 Dec;315(3):971-9. Epub 2005 Jul 7. Review.
Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology. 2013 Oct 1;2(10):e26333.
Coulson A, Levy A, Gossell-Williams M. Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. West Indian Med J. 2014 Jul 3;63(6):650-4.
Weıgert K, Lewgoy J, Mazzolenı DS, Franco FR, Enrıconı L, Sasso JH. Rituximab And Osteonecrosis of The Jaws: Case Study. Oral Medicine, Oral Pathology, 2014;117(2):e188-e9.
Allegra A, Oteri G, Alonci A, Bacci F, Penna G, Minardi V, Maisano V, Musolino C. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg. 2014 Jun;42(4):279-82.
Cassoni A, Romeo U, Terenzi V, Della Monaca M, Rajabtork Zadeh O, Raponi I, Fadda MT, Polimeni A, Valentini V. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? Case Rep Dent. 2016;2016:2856926.
Favia G, Tempesta A, Limongelli L, Crincoli V, Iannone F, Lapadula G, Maiorano E. A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab. Am J Case Rep. 2017 Dec 19 [revised 2017 Jan 1];18:1351-1356.